

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:


1-18. (Canceled).

19. (previously presented): A cell targeting conjugate comprising the following components that are covalently conjugated via a hydrazine, disulphide or amide bond linker that is degradable within the target cells:

a DNA minor groove binding ligand incorporating an effective Auger electron-emitting, gamma-emitting or positron-emitting atom or photoactive moiety;

a target cell specific protein or peptide that is capable of internalisation by target cells;

wherein the cell targeting conjugate is represented by Formula (I), wherein:



Formula (I)

X is carbon or nitrogen;

Y₁ and Y₂ are selected from C(R'), nitrogen, N(R'), oxygen and sulfur, wherein R' is

hydrogen, optionally substituted alkyl or optionally substituted alkenyl, and wherein Y₁ and Y₂ are not both either C(R') or nitrogen;

— is a double bond unless the attached Y₁ or Y₂ is N(R'), oxygen or sulfur in which case it is a single bond;

R₁ to R₁₂ are selected from hydrogen, halogen, hydroxy, amino, optionally substituted alkyl, optionally substituted alkenyl, a moiety including a target cell specific protein or peptide, an Auger electron-emitting moiety, a gamma-emitting moiety, a positron-emitting moiety and a photoactive moiety, and wherein two of R₁ to R₅ may together form optionally substituted cycloalkyl, cycloalkenyl or aryl; wherein one of R₁ to R₁₂ comprises a target cell specific protein or peptide, and wherein one other of R₁ to R₁₂ comprises an Auger electron-emitting moiety, a gamma-emitting moiety, a positron-emitting moiety or a photoactive moiety;

and salts and/or tautomers thereof.

20. (Canceled).

21. (previously presented): The cell targeting conjugate according to claim 19 wherein the target cell specific protein or peptide is selected from anti-A33, C595, 4D5, trastuzumab, egf/R3, humanized h-R3, C225, BrE-3, murine A7, C50, humanized MN-14, anti-A33, MSN-1, bivatuzumab, U36, KIS1, HuM195, anti-CD45, anti-CD19, TXU(anti-CD7)-pokeweed antiviral protein, M195, anti-CD23, apolizumab (Hu1D10), Campath-1H, N901, Ep2, somatostatin analogues, tositumomab, ibritumomab tiuxetan, HB22.7, anti-CD40, OC125, PAM4 and J591.


22-31. (Canceled).

32. (previously presented) The cell targeting conjugate according to claim 19 wherein the gamma-emitting or positron-emitting moiety is distanced from a DNA minor groove binding region of the conjugate.


33. (Canceled).

34. (Canceled).

35. (Currently amended): A cell targeting conjugate according to claim 32 selected from the following:



and



wherein R represents hydrogen, hydroxy, amino, halogen or optionally substituted alkyl, alkenyl or alkynyl, and wherein I represents the gamma-emitting or positron-emitting moiety wherein the gamma-emitting or positron-emitting moiety is iodine (I).